Erratum. 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes-2024. Diabetes Care 2024;47(Suppl. 1):S158-S178.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

15 citing papers in PubMed, 1 synthesis or guideline pooled it, 28 citations in OpenAlex.

1. [Cardiovascular preventive recommendations. PAPPS 2024 thematic updates].Atencion primaria · 2024
   Guideline
2. Real-world treatment patterns and cost per patient achieving treatment targets among tirzepatide and semaglutide initiators in US patients with type 2 diabetes.Journal of managed care & specialty pharmacy · 2026
   Article
3. Beyond the Individual: Couple-Centered Health and Wellness Coaching to Address the Burden of Chronic Conditions.Preventing chronic disease · 2026
   Article
4. Dietary Patterns, Type 2 Diabetes Awareness, and Anthropometric Risk Factors Among African American Students at a Historically Black College and University: A Cross-Sectional Study.Research square · 2026
   Article
5. Data Privacy, Ownership, and Secondary Use of Clinical Data Generated by Continuous Glucose Monitors and Mobile Health Applications: A Review.Journal of diabetes science and technology · 2026
   Review
6. Impact of specialised endocrinology care on metabolic control and healthcare utilisation outcomes after kidney transplantation in patients with diabetes: A 12-month observational cohort study.Diabetes, obesity & metabolism · 2026
   Observational
7. Peripapillary Retinal and Choroidal Vasculature in Patients with Diabetes of Different Durations without Clinical Diabetic Retinopathy.Diabetes, metabolic syndrome and obesity : targets and therapy · 2026
   Article
8. Oral health-related quality of life and diabetes outcomes: Evidence from a nationally representative U.S. sample.Journal of dental sciences · 2026
   Article
9. Win-Win Pricing of Follow-Up Policies Under Healthcare Warranties for Chronic Diseases: A Mathematical Modeling Approach.Healthcare (Basel, Switzerland) · 2025
   Article
10. Enhancing Antidiabetic Drug Selection Using Transformers: Machine-Learning Model Development.JMIR medical informatics · 2025
    Article
11. Effect of beinaglutide, a thrice-daily GLP-1 receptor agonist, on body weight and metabolic parameters: A systematic review and meta-analysis.World journal of diabetes · 2025
    Article
12. Idebenone: Clinical Potential Beyond Neurological Diseases.Drug design, development and therapy · 2025
    Review
13. A prospective, multicentre study evaluating safety and efficacy of a fixed dose combination of Remogliflozin etabonate, Vildagliptin, and Metformin in Indian patients with type 2 diabetes mellitus (Triad-RMV).Clinical diabetes and endocrinology · 2024
    Article
14. Cardiorenal effects of therapies for type 2 diabetes and obesity.The British journal of cardiology · 2024
    Article
15. "Coach in your pocket": Men's digital self-management of type 2 diabetes.Digital health
    Article

Corrections and comments

• Erratum for
  9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes-2024.2024

Authors and funding

1 author.

Funding

Abstract

PubMed holds no abstract for this paper.